Nephros Future Growth

Future criteria checks 4/6

Nephros is forecast to grow earnings and revenue by 107% and 13.9% per annum respectively while EPS is expected to grow by 108% per annum.

Key information

107.0%

Earnings growth rate

108.0%

EPS growth rate

Consumer Durables earnings growth	8.0%
Revenue growth rate	13.9%
Future return on equity	n/a
Analyst coverage	Low
Last updated	08 Mar 2024

Recent future growth updates

Recent updates

After Leaping 40% Nephros, Inc. (NASDAQ:NEPH) Shares Are Not Flying Under The Radar

Dec 18

At US$3.18, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?

Dec 14

Nephros partners with Donastar and Tractor Beverage to supply and service nationwide fast-casual restaurant operation

Sep 28

US$5.13: That's What Analysts Think Nephros, Inc. (NASDAQ:NEPH) Is Worth After Its Latest Results

Aug 13

Market Sentiment Around Loss-Making Nephros, Inc. (NASDAQ:NEPH)

Mar 25

At US$8.37, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?

Mar 04

Announcing: Nephros (NASDAQ:NEPH) Stock Increased An Energizing 131% In The Last Five Years

Jan 28

Earnings and Revenue Growth Forecasts

NasdaqCM:NEPH - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	19	0	N/A	N/A	1
12/31/2024	17	-1	N/A	N/A	2
12/31/2023	14	-2	1	1	N/A
9/30/2023	14	-2	1	1	N/A
6/30/2023	12	-3	0	0	N/A
3/31/2023	12	-3	-1	-1	N/A
12/31/2022	10	-5	-3	-3	N/A
9/30/2022	10	-5	-4	-3	N/A
6/30/2022	10	-4	-4	-4	N/A
3/31/2022	10	-4	-3	-3	N/A
12/31/2021	10	-3	-2	-1	N/A
9/30/2021	10	-3	-3	-3	N/A
6/30/2021	9	-4	-4	-4	N/A
3/31/2021	9	-4	-5	-5	N/A
12/31/2020	9	-5	-7	-7	N/A
9/30/2020	9	-4	-5	-5	N/A
6/30/2020	10	-4	-4	-4	N/A
3/31/2020	11	-3	-3	-3	N/A
12/31/2019	10	-3	-2	-2	N/A
9/30/2019	9	-4	-3	-3	N/A
6/30/2019	7	-4	-4	-4	N/A
3/31/2019	6	-3	-4	-4	N/A
12/31/2018	6	-3	-4	-4	N/A
9/30/2018	5	-1	-1	-1	N/A
6/30/2018	5	-1	-1	-1	N/A
3/31/2018	4	-2	0	0	N/A
12/31/2017	4	-1	0	0	N/A
9/30/2017	3	-3	N/A	-2	N/A
6/30/2017	3	-3	N/A	-2	N/A
3/31/2017	2	-3	N/A	-2	N/A
12/31/2016	2	-3	N/A	-2	N/A
9/30/2016	2	-3	N/A	-3	N/A
6/30/2016	2	-3	N/A	-3	N/A
3/31/2016	2	-4	N/A	-3	N/A
12/31/2015	2	-3	N/A	-4	N/A
9/30/2015	2	-3	N/A	-3	N/A
6/30/2015	2	0	N/A	-3	N/A
3/31/2015	2	-4	N/A	-3	N/A
12/31/2014	2	-7	N/A	-2	N/A
9/30/2014	2	-2	N/A	-3	N/A
6/30/2014	2	-6	N/A	-2	N/A
3/31/2014	2	-1	N/A	-3	N/A
12/31/2013	2	1	N/A	-4	N/A
9/30/2013	2	-4	N/A	-3	N/A
6/30/2013	2	-4	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NEPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: NEPH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NEPH is expected to become profitable in the next 3 years.

Revenue vs Market: NEPH's revenue (13.9% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: NEPH's revenue (13.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NEPH's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Nephros Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Consensus EPS estimates upgraded to US$0.12 loss

Consensus estimates of losses per share improve by 30%

Forecast to breakeven in 2025

No longer forecast to breakeven

Forecast to breakeven in 2024

Consensus EPS estimates fall by 37%

Recent updates

Nephros, Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Nephros, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Now 21% undervalued

Now 25% undervalued

After Leaping 40% Nephros, Inc. (NASDAQ:NEPH) Shares Are Not Flying Under The Radar

At US$3.18, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?

Consensus EPS estimates upgraded to US$0.12 loss

Consensus estimates of losses per share improve by 30%

Forecast to breakeven in 2025

Nephros, Inc., Hires Judy Krandel as Chief Financial Officer

Nephros, Inc., Hires Judy Krandel as Chief Financial Officer

Nephros, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Nephros, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Share price stability

No longer forecast to breakeven

First quarter 2023 earnings: EPS misses analyst expectations

Nephros, Inc. Announces CEO Changes

Forecast to breakeven in 2024

Consensus EPS estimates fall by 37%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased by 27% to US$3.00

Less than half of directors are independent

Nephros, Inc. Announces Board Changes

Nephros, Inc. to Report Q4, 2022 Results on Mar 08, 2023

Nephros, Inc. announced delayed 10-Q filing

Price target decreased to US$3.63

Consensus EPS estimates fall by 23%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Nephros, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Nephros partners with Donastar and Tractor Beverage to supply and service nationwide fast-casual restaurant operation

Nephros Appoints Joe Harris to Its Board of Directors

Wes Lobo, Chief Commercial Officer of Nephros, Inc. Resigns, to Be Effective No Later Than September 30, 2022

US$5.13: That's What Analysts Think Nephros, Inc. (NASDAQ:NEPH) Is Worth After Its Latest Results

Second quarter 2022 earnings: EPS exceeds analyst expectations

Nephros, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Nephros Receives FDA 510(k) Clearance for HDF Assist Module

Consensus revenue estimates fall by 17%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$9.33

Nephros, Inc., Annual General Meeting, May 19, 2022

Full year 2021 earnings: EPS misses analyst expectations

Nephros, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2022

Price target decreased to US$12.33

Nephros, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021 and for the Year 2022

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.12 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.19 loss in 2Q 2020)

Forecast to breakeven in 2023

No longer forecast to breakeven

Consensus revenue estimates fall to US$10.9m

First quarter 2021 earnings released: US$0.06 loss per share (vs US$0.14 loss in 1Q 2020)

Nephros, Inc. Provides Revenue Guidance for the Quarter Ended March 31, 2021

Market Sentiment Around Loss-Making Nephros, Inc. (NASDAQ:NEPH)

Analysts lower revenue estimates to US$11.5m

At US$8.37, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?

Full year 2020 earnings released: US$0.53 loss per share (vs US$0.45 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Nephros, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Nephros, Inc. Hires Wes Lobo as Chief Marketing Officer

New 90-day high: US$8.93

Nephros, Inc. Announces Management Changes

Chief Financial Officer has left the company

Announcing: Nephros (NASDAQ:NEPH) Stock Increased An Energizing 131% In The Last Five Years

Nephros sees Q4 revenue in-line with estimates,

New 90-day high: US$7.39